An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients
A 2-Part, Open Label Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Chronically Infected With Genotype 1 Hepatitis C Virus Following Liver Transplantation
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
Alberta
-
Calgary, Alberta, Kanada
-
-
British Columbia
-
Vancouver, British Columbia, Kanada
-
-
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten
- Alabama
-
-
Arizona
-
Phoenix, Arizona, Vereinigte Staaten
- Arizona
-
-
California
-
Los Angeles, California, Vereinigte Staaten
- California
-
-
Colorado
-
Denver, Colorado, Vereinigte Staaten
- Colorado
-
-
Florida
-
Bradenton, Florida, Vereinigte Staaten
- Florida
-
Miami, Florida, Vereinigte Staaten
- Florida
-
-
Illinois
-
Evanston, Illinois, Vereinigte Staaten
- Illinios
-
-
Indiana
-
Indianapolis, Indiana, Vereinigte Staaten
- Indiana
-
-
Massachusetts
-
Burlington, Massachusetts, Vereinigte Staaten
- Massachusetts
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten
- Michigan
-
Detroit, Michigan, Vereinigte Staaten
- Michigan
-
-
Missouri
-
St Louis, Missouri, Vereinigte Staaten
- Missouri
-
-
Nebraska
-
Omaha, Nebraska, Vereinigte Staaten
- Nebraska
-
-
New York
-
New York, New York, Vereinigte Staaten
- New York
-
Rochester, New York, Vereinigte Staaten
- New York
-
-
North Carolina
-
Charlotte, North Carolina, Vereinigte Staaten
- North Carolina
-
-
Ohio
-
Cleveland, Ohio, Vereinigte Staaten
- Ohio
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten
- Pennsylvania
-
-
Texas
-
Dallas, Texas, Vereinigte Staaten
- Texas
-
Houston, Texas, Vereinigte Staaten
- Texas
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Male and female participants between the ages of 18 and 65 years
- History of orthotopic liver transplantation less than 10 years before the Screening visit but no sooner than 6 months before Day 1
- Taking a stable immunosuppressant regimen based on either tacrolimus or cyclosporine without substantial dose changes over the past 3 months
- Naive to pegylated interferon/ribavirin treatment or experienced with pegylated interferon/ribavirin prior to transplantation with relapse, partial, or null response
Exclusion Criteria:
- Documented cirrhosis after liver transplantation
- Ascites or hepatic encephalopathy within 6 months before Screening
- Retransplantation for recurrent hepatitis C
- Treatment for hepatitis C post liver transplantation
- History within the past 3 months of: rejection within 3 months or greater than (>) 1 rejection within 12 months
- Current treatment with sirolimus or methylprednisolone. Low dose prednisone use (<5 milligram per day) is permitted
- History within 3 months of any bacterial infection requiring >1 week of intravenous antibiotics, cytomegalovirus viremia or cytomegalovirus infection with end-organ involvement, fungal disease (except cutaneous and mild oral thrush)
- History of post transplant lymphoproliferative disease
- Acceptable laboratory values at Screening as specified in the protocol
- Positive for human immunodeficiency virus 1/2 (HIV1/2) enzyme immunoassay (EIA) antibody screen or Hepatitis B deoxyribonucleic acid (DNA) or Hepatitis B surface antigen
- History of hepatocellular carcinoma with high risk of recurrence
- Any other cause of liver disease deemed clinically significant by the investigator in addition to hepatitis C
- Autoimmune-mediated disease
- History of acute pancreatitis within 5 years before the Screening visit
- Prior treatment with an hepatitis C virus (HCV) protease inhibitor
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: T/PR + Immunosuppressant Regimen (Tacrolimus)
Participants who were receiving tacrolimus (TAC) based immunosuppressant regimen at baseline, received telaprevir (T) 1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 48 weeks.
Participants continued their immunosuppressant regimen, as per standard practice and investigator discretion.
|
Tablette
Andere Namen:
Tablette
Andere Namen:
Subkutane Injektion
Andere Namen:
Cyclosporine (CsA) based immunosuppressant regimen or Tacrolimus (TAC) based immunosuppressant regimen, as per standard practice.
Immunosuppressant regimen were not considered study drugs.
|
|
Experimental: T/PR + Immunosuppressant Regimen (Cyclosporine)
Participants who were receiving cyclosporine (CsA) based immunosuppressant regimen at baseline, received telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks.
Participants continued their immunosuppressant regimen, as per standard practice and investigator discretion.
|
Tablette
Andere Namen:
Tablette
Andere Namen:
Subkutane Injektion
Andere Namen:
Cyclosporine (CsA) based immunosuppressant regimen or Tacrolimus (TAC) based immunosuppressant regimen, as per standard practice.
Immunosuppressant regimen were not considered study drugs.
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of Participants With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)
Zeitfenster: 12 weeks after last planned dose of study drug (up to Week 60)
|
SVR12 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (<lower limit of quantification) at 12 weeks after last planned dose of study treatment.
The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay.
The lower limit of quantification was 25 international units per milliliter (IU/mL).
|
12 weeks after last planned dose of study drug (up to Week 60)
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of Participants With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR24)
Zeitfenster: 24 weeks after last planned dose of study drug (up to Week 72)
|
SVR24 was defined as an undetectable HCV RNA Levels at 24 weeks after last planned dose of study treatment.
The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay.
The lower limit of quantification was 25 IU/mL.
|
24 weeks after last planned dose of study drug (up to Week 72)
|
|
Percentage of Participants With Rapid Viral Response (RVR)
Zeitfenster: Week 4
|
The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay.
The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL.
RVR was defined as undetectable HCV RNA 4 weeks after the start of study treatment.
|
Week 4
|
|
Percentage of Participants With Extended Rapid Viral Response (eRVR)
Zeitfenster: Week 4 and Week 12
|
The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay.
The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL.
eRVR was defined as undetectable HCV RNA at both 4 weeks and 12 weeks after the start of study treatment.
|
Week 4 and Week 12
|
|
Percentage of Participants With On-Treatment Virologic Failure
Zeitfenster: Baseline up to Week 48
|
On-treatment virologic failure was defined as subjects who met futility or who completed the assigned treatment duration and had detectable HCV RNA at planned end of treatment (up to 48 weeks).
Data for this outcome was not planned to be reported by prior response.
|
Baseline up to Week 48
|
|
Percentage of Participants With Viral Relapse
Zeitfenster: 48 weeks
|
48 weeks
|
|
|
Pharmacokinetics of Telaprevir, Peg-IFN, RBV , and Selected Immunosuppressant Medications (Tacrolimus and Cyclosporine)
Zeitfenster: 48 weeks
|
48 weeks
|
|
|
Percentage of Participants Requiring Dose Titration of Immunosuppressant Medications
Zeitfenster: 48 weeks
|
48 weeks
|
|
|
Percentage of Participants With Biopsy Confirmed and Treated Rejection
Zeitfenster: 48 weeks
|
48 weeks
|
|
|
Percentage of Participants With Histological Evidence of Stabilization or Improvement in Inflammation Grade or Fibrosis Stage
Zeitfenster: 48 weeks
|
48 weeks
|
|
|
Number of Participants With Telaprevir Resistant HCV Variant at Non-Structural Viral Protein 3-4A (NS3-4A) Region
Zeitfenster: 48 weeks
|
48 weeks
|
|
|
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Zeitfenster: Baseline up to Week 52
|
Any adverse change from the participant's baseline (pre-treatment) condition, including any adverse experience, abnormal recording or clinical laboratory assessment value which occurs during the course of the study, whether it is considered related to the study drug or not.
An adverse event includes any newly occurring event or previous condition that has increased in severity or frequency since the administration of study drug.
SAE: medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event.
"Study drug" includes all investigational agents (including placebo, if applicable) administered during the course of the study.
|
Baseline up to Week 52
|
Andere Ergebnismessungen
Andere Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Percentage of Participants With Sustained Viral Response 4 Weeks After Last Planned Dose of Study Drug (SVR4)
Zeitfenster: 4 weeks after last planned dose of study drug (up to Week 52)
|
4 weeks after last planned dose of study drug (up to Week 52)
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Verdauungssystems
- RNA-Virusinfektionen
- Viruserkrankungen
- Infektionen
- Durch Blut übertragene Infektionen
- Übertragbare Krankheiten
- Leberkrankheiten
- Flaviviridae-Infektionen
- Hepatitis, viral, menschlich
- Hepatitis
- Hepatitis C
- Physiologische Wirkungen von Arzneimitteln
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antiinfektiva
- Antivirale Mittel
- Antimetaboliten
- Antineoplastische Mittel
- Immunologische Faktoren
- Interferone
- Interferon-alpha
- Ribavirin
- Peginterferon alfa-2a
- Interferon alpha-2
- Immunsuppressive Mittel
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- VX11-950-117
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .